Sponsor:
Kartos Therapeutics, Inc.
Code:
NCT06479135
Conditions
Myelofibrosis
Post-PV MF
Post-ET Myelofibrosis
Primary Myelofibrosis
MF
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Navtemadlin
Navtemadlin placebo
Ruxolitinib
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Kartos Therapeutics, Inc. on 2024-12-24.